基于CT影像组学评估胃癌D2切除术后追加放疗的获益
该回顾性研究纳入154例D2淋巴结清扫术后接受化疗或放化疗的胃癌患者,基于增强CT提取影像组学特征预测总生存和无病生存。影像组学评分预测无病生存的C指数为0.721(95%CI: 0.681-0.761),预测总生存的C指数为0.774(95%CI: 0.738-0.810)。追加放疗的获益仅在Lauren肠型且伴神经周围侵犯的亚组中观察到。
要点
- 增强CT影像组学可预测胃癌D2切除术后化疗或放化疗患者的总生存和无病生存。
- 追加放疗的获益仅在Lauren肠型且伴神经周围侵犯的胃癌亚组中观察到。
- 整合临床因素后影像组学模型预测无病生存C指数0.773(95%CI: 0.736-0.810)、总生存0.802(95%CI: 0.765-0.839)。
核心结论
- 基于增强CT的影像组学预测胃癌D2切除术后接受化疗和放化疗患者的总生存和无病生存是可行的;追加放疗的获益仅在Lauren肠型且伴神经周围侵犯的胃癌患者中观察到。
研究设计与样本
- 回顾性研究,共154例在作者所在医院接受化疗和放化疗的胃癌患者,随机按7:3分为训练队列和测试队列;从增强CT勾画的肿瘤体积中使用pyradiomics软件提取影像组学特征。
诊断标准与关键数值
- 影像组学评分预测无病生存的C指数为0.721(95%CI: 0.681-0.761)。
- 影像组学评分预测总生存的C指数为0.774(95%CI: 0.738-0.810)。
- 整合临床因素后模型预测无病生存的C指数为0.773(95%CI: 0.736-0.810)。
- 整合临床因素后模型预测总生存的C指数为0.802(95%CI: 0.765-0.839)。
临床应用与阅片要点
- 作者认为基于增强CT的影像组学预测胃癌D2切除术后化疗和放化疗患者的总生存和无病生存是可行的。
- 作者观察到追加放疗的获益仅见于Lauren肠型且伴神经周围侵犯的胃癌患者亚组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The value of adding radiotherapy (RT) is still unclear for patients with gastric cancer (GC) after D2 lymphadenectomy. The purpose of this study is to predict and compare the overall survival (OS) and disease-free survival (DFS) of GC patients treated by chemotherapy and chemoradiation based on contrast-enhanced CT (CECT) radiomics.
METHODS: A total of 154 patients treated by chemotherapy and chemoradiation in authors' hospital were retrospectively reviewed and randomly divided into the training and testing cohorts (7:3). Radiomics features were extracted from contoured tumor volumes in CECT using the pyradiomics software. Radiomics score and nomogram with integrated clinical factors were developed to predict the OS and DFS and evaluated with Harrell's Consistency Index (C-index).
RESULTS: Radiomics score achieved a C index of 0.721(95%CI: 0.681-0.761) and 0.774 (95%CI: 0.738-0.810) in the prediction of DFS and OS for GC patients treated by chemotherapy and chemoradiation, respectively. The benefits of additional RT only demonstrated in subgroup of GC patients with Lauren intestinal type and perineural invasion (PNI). Integrating clinical factors further improved the prediction ability of radiomics models with a C-index of 0.773 (95%CI: 0.736-0.810) and 0.802 (95%CI: 0.765-0.839) for DFS and OS, respectively.
CONCLUSIONS: CECT based radiomics is feasible to predict the OS and DFS for GC patients underwent chemotherapy and chemoradiation after D2 resection. The benefits of additional RT only observed in GC patients with intestinal cancer and PNI.
引用
- Zheng, Zheng, Jiang, et al. Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics. Radiol Med. 2023. PMID: 37188857. doi:10.1007/s11547-023-01646-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。